| COVID-19 Clinical Research Studies | Lifetime | 462 | AR 1 | 98.17 |
| Lipoproteins and Cardiovascular Health | Lifetime | 229 | AR 1 | 98.92 |
| Cancer, Lipids, and Metabolism | Lifetime | 350 | AR 1 | 98.59 |
| Diabetes, Cardiovascular Risks, and Lipoproteins | Lifetime | 292 | AR 1 | 98.91 |
| Diabetes Treatment and Management | Lifetime | 340 | AR 1 | 98.70 |
| Lipid metabolism and disorders | Lifetime | 199 | AR 1 | 97.68 |
| Atherosclerosis and Cardiovascular Diseases | Lifetime | 344 | AR 1 | 97.62 |
| Metabolism, Diabetes, and Cancer | Lifetime | 652 | AR 1 | 97.65 |
| Cardiovascular Health and Disease Prevention | Lifetime | 643 | AR 1 | 97.24 |
| Pharmacology and Obesity Treatment | Lifetime | 238 | AR 1 | 97.27 |
| Adipokines, Inflammation, and Metabolic Diseases | Lifetime | 703 | AR 1 | 97.13 |
| Older Adults Driving Studies | Lifetime | 411 | AR 1 | 85.84 |
| Spatial Neglect and Hemispheric Dysfunction | Lifetime | 673 | AR 3 | 85.40 |
| Diabetes Treatment and Management | 2021-2025 | 49 | AR 1 | 99.51 |
| Metabolism, Diabetes, and Cancer | 2021-2025 | 26 | AR 1 | 99.08 |
| Diabetes, Cardiovascular Risks, and Lipoproteins | 2021-2025 | 40 | AR 1 | 98.63 |
| Diet and metabolism studies | 2021-2025 | 209 | AR 1 | 97.54 |
| Lipoproteins and Cardiovascular Health | 2021-2025 | 76 | AR 1 | 98.04 |
| Liver Disease Diagnosis and Treatment | 2021-2025 | 398 | AR 3 | 98.07 |
| Diet, Metabolism, and Disease | 2021-2025 | 80 | AR 2 | 97.50 |
| COVID-19 Clinical Research Studies | 2021-2025 | 826 | AR 1 | 96.58 |
| Pharmacology and Obesity Treatment | 2021-2025 | 32 | AR 1 | 97.04 |
| Cancer, Lipids, and Metabolism | 2021-2025 | 238 | AR 1 | 93.31 |
| Pancreatic function and diabetes | 2021-2025 | 331 | AR 1 | 94.28 |
| Diabetes Management and Research | 2021-2025 | 489 | AR 1 | 94.59 |
| Atherosclerosis and Cardiovascular Diseases | 2021-2025 | 304 | AR 2 | 88.14 |
| Peroxisome Proliferator-Activated Receptors | 2021-2025 | 131 | AR 1 | 85.19 |
| Hyperglycemia and glycemic control in critically ill and hospitalized patients | 2021-2025 | 161 | AR 1 | 86.79 |
| Neuropeptides and Animal Physiology | 2021-2025 | 293 | AR 1 | 84.68 |
| Adipokines, Inflammation, and Metabolic Diseases | 2021-2025 | 568 | AR 1 | 82.24 |
| Cardiovascular Health and Disease Prevention | 2021-2025 | 804 | AR 1 | 83.37 |
| Lipid metabolism and disorders | 2021-2025 | 430 | AR 5 | 73.16 |
| Potassium and Related Disorders | 2021-2025 | 702 | AR 1 | 61.02 |
